■评估经颈椎间孔腔硬膜外类固醇注射(CTFESI)治疗单侧颈神经根痛的有效性。
■单组前瞻性队列研究。
■结果包括手臂疼痛的数字评定量表(NRS)降低≥50%,颈部残疾指数(NDI-5)改善≥30%,健康相关生活质量(EQ-5D),全球改进(PGIC),个人目标成就(COMBI),慢性疼痛睡眠指数(CPSI)以及医疗保健利用率,三,六,和12个月。数据分析包括描述性统计和95%置信区间(CI)的计算,列联表分析,和多水平逻辑回归(LR)分析,包括最坏情况(WC)敏感性分析,其中缺失数据被视为治疗失败。接受手术治疗的参与者在分类分析中被认为是失败的。
■33名连续登记的参与者(63.6%为女性,51.2±12.2岁,BMI28.3±4.5kg/m2)进行分析。手臂疼痛的NRS降低≥50%的成功率,三,6个月和12个月为57.6%(95%CI40.8-72.8%),71.9%(95%CI54.6-84.4%),64.5%(95%CI46.9-78.9%),和64.5%(95%CI46.9-78.9%)。NDI-5改善≥30%的成功率为60.6%(95%CI43.7-75.3%),68.8%(95%CI51.4-82.0%),61.3%(95%CI43.8-76.3%),和71.0%(95%CI53.4-83.9%)。在WC分析中,≥50%的NRS和NDI-5组患者在1~12个月间的成功率降低0~4.3%.PGIC分数至少“大大提高”或“非常提高”,“48.4-65.6%的参与者在1到12个月之间。6.1%,6.1%,3.0%有一个,两个,或三次重复注射,分别。18.2%的参与者在12个月后接受了手术。参与者在治疗后显示手臂NRS和NDI-5的显着改善(p<0.05),多水平logistic回归模型显示,随访时间点改善无显著下降(p>0.05).
■在CTFESI治疗12个月后,在疼痛和残疾方面观察到有统计学意义和临床意义的改善。
UNASSIGNED: To evaluate the effectiveness of cervical
transforaminal epidural steroid injection (CTFESI) for the treatment of unilateral cervical radicular pain.
UNASSIGNED: Single-group prospective cohort study.
UNASSIGNED: Outcomes included ≥50% reductions in Numeric Rating Scale (NRS) for arm pain, ≥30% Neck Disability Index (NDI-5) improvement, health-related quality of life (EQ-5D), global improvement (PGIC), personal goal achievement (COMBI), Chronic Pain Sleep Index (CPSI), and healthcare utilization at one, three, six, and 12 months. Data analysis included descriptive statistics with the calculations of 95% confidence intervals (CIs), contingency table analysis, and multilevel logistic regression (LR) analysis, including a worst-case (WC) sensitivity analysis in which missing data were treated as treatment failure. Participants who were treated surgically were considered failures in the categorical analyses.
UNASSIGNED: 33 consecutively enrolled participants (63.6% females, 51.2 ± 12.2 years of age, BMI 28.3 ± 4.5 kg/m2) were analyzed. Success rates for ≥50% reduction in NRS for arm pain at one, three, six and 12 months were 57.6% (95% CI 40.8-72.8%), 71.9% (95% CI 54.6-84.4%), 64.5% (95% CI 46.9-78.9%), and 64.5% (95% CI 46.9-78.9%). Success rates for ≥30% improvement in NDI-5 were 60.6% (95% CI 43.7-75.3%), 68.8% (95% CI 51.4-82.0%), 61.3% (95% CI 43.8-76.3%), and 71.0% (95% CI 53.4-83.9%). In WC analysis, success rates for ≥50% arm NRS and NDI-5 were 0-4.3% lower between 1 and 12 months. PGIC scores were at least \"much improved\" or \"very much improved,\" in 48.4-65.6% of participants between 1 and 12 months. 6.1%, 6.1%, and 3.0% had one, two, or three repeat injections, respectively. 18.2% of participants underwent surgery by 12 months. Participants showed significant improvements in arm NRS and NDI-5 after treatment (p < 0.05), multilevel logistic regression models showed no significant decline in improvements across the follow-up time points (p > 0.05).
UNASSIGNED: Statistically significant and clinically meaningful improvements in pain and disability were observed after CTFESI for up to 12 months in individuals with unilateral cervical radicular pain.